News
Why This Investment Advisor Sold Off Its $3.6 Million Bruker Stake
On Tuesday, Massachusetts-based Lane Generational disclosed that it sold out of Bruker (NASDAQ:BRKR), liquidating 87,607 shares for an estimated $3.6 million in the third quarter.
According to a
EQS-News: In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties
Schwartz Offloads 28,000 Chemed (CHE) Shares Valued at $13 Million
Schwartz Investment Counsel disclosed that it reduced its position in Chemed Corporation (NYSE:CHE) by 28,771 shares during the quarter, according to a 13F form filed with the Securities and
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by
Why Omnicell Stock Crushed the Market Today
Healthcare tech company Omnicell (NASDAQ: OMCL) was quite the picture of health on Thursday, at least as far as its equity was concerned. An encouraging quarterly earnings report sent its shares
EULAV Asset Management Unloads $13 Million of Chemed (NYSE: CHE) Stock: Should Investors Sell Too?
On October 28, 2025, EULAV Asset Management reported selling 28,313 shares of Chemed (NYSE:CHE) in Q3 2025, an estimated $12.82 million trade based on the average price during Q3 2025.
According to
EQS-News: Evotec SE to announce results for the first nine months 2025 on 05 November 2025
EQS-News: Gerresheimer: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen
EQS-Adhoc: Gerresheimer AG: Uwe Röhrhoff takes over as interim CEO for Dietmar Siemssen
Prediction: Nvidia Stock Could Reach $360 Sooner Than You Think
Nvidia (NASDAQ: NVDA) is transforming from a graphics processing unit (GPU) champion to an artificial intelligence (AI) infrastructure cash engine. Learn about Blackwell, DGX Spark, and DGX Cloud
EQS-News: Evotec announces progress in preclinical neuroscience partnership with Bristol Myers Squibb
Meet the Biotech Stock That Just Jumped 251% Higher
Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can
EQS-Adhoc: Gerresheimer AG: Initial findings of an external independent investigation into revenue recognition from bill-and-hold agreements in the 2024 financial year
EQS-News: Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months
The Ultimate Biotech Stock to Buy With $50 Right Now
Finding great biotech stocks to invest in at a price point of $50 per share (or less) isn't easy. There are plenty of companies in the industry trading for far less money than that, but they tend to
Why Scholar Rock Stock Got Socked on Monday
A potential delay in an important submission was the news item driving Scholar Rock's (NASDAQ: SRRK) share price down as the trading week kicked off. On Monday, the biotech's shares fell by more
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street
Nektar Therapeutics (NASDAQ: NKTR) is a small-cap biotech that has garnered plenty of attention this year. The company's shares have soared, increasing by 285% since January. Yet, some analysts
EQS-News: Gerresheimer: FDA grants Approval of SQ Innovation’s Lasix® ONYU*
EQS-News: Gerresheimer: Business performance and slower market growth require guidance adjustment
EQS-Adhoc: Gerresheimer AG: Business performance and slower market growth require adjustment of guidance for 2025
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September
Shares of Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company, shot 90.6% higher in October, according to data from S&P Global Market Intelligence. Investors have been increasingly
EQS-News: Gerresheimer Expands Wertheim Site with new Production Facility for Ready-to-fill Vials
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years
Every investor wants to outperform the market, but it's a challenging feat to achieve. That's why few manage to do it consistently over long periods. What's the best approach to take? Day trading is
EQS-News: Gerresheimer comments on the audit by German BaFin
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?
Investors in the biotechnology space have been treated to a couple of big fireworks displays recently. During the month leading up to Sept. 19, shares of Nektar Therapeutics (NASDAQ: NKTR) and